Today is World Health Day, a day to remind ourselves that while we have overcome many global health challenges, at least half of the world’s population is unable to obtain essential health services. According to the World Health Organization, more than 800 million people spend at least 10 percent of their household budget on healthcare today. Even more alarming is the fact that each year close to 100 million people are being pushed into “extreme poverty” due to healthcare expenses.

As the bar rises, we must continue to strive to provide access to healthcare for our 7 billion neighbors around the world. Healthcare is a basic human right, not a privilege. How can we solve this problem? Read more. 

---

March 29, 2018

An HIV Success Story

Mylan continues to fight for access to high-quality medicine and one of our best success stories is for people living with HIV.  While I continue to be an advocate to fix our broken healthcare system and work to find solutions for the patient at the pharmacy counter, I equally want to call attention to what is working. Read more.

---

March 8, 2018

From the Family Room to the Board Room

I can't help but wonder what the world might look like today if all – not just half – of the world’s great minds over the centuries had been recognized and their full potential tapped. I think about illnesses that might now be distant memories, injustices that could have been avoided and great works of art that may have changed the world for the better. For all these reasons and more, I regard this year’s International Women’s Day’s theme, #PressforProgress, as a poignant reminder of the work still ahead of us to achieve gender equality. Read more.

---

March 2, 2018

Mylan Is That Company!

I recognize that a recurring theme across the U.S. healthcare sector right now is the ongoing challenges that many companies are facing.

Those challenges are causing many to wonder what the future holds for our industry. Read more.

---

February 21, 2018

I’m passionate about Mylan’s work to fight HIV/AIDS. More than 40% of people being treated around the world depend on a Mylan product.

This week, our work to continue to set new standards for affordable access for patients in countries hardest hit by HIV/AIDS took another step forward. The U.S. Food and Drug Administration announced the tentative approval under the U.S. President's Emergency Plan for AIDS Relief of our Dolutegravir, Emtricitabine and Tenofovir Alafenamide Tablets.

The product will be immediately available in developing countries as a first-line regimen for people being treated for the disease. The tablet will be the smallest sized single-tablet regimen available for patients in the developing world. And by offering 90-day and 30-day packages, we hope patients can make fewer trips to clinics to get refills.

Our commitment to continue to innovate and expand access has never been stronger. The world needs more cost competitive and clinically effective products like this one, which is why Mylan is proud to work with partners to make it available and help reach the more than 15 million people living with HIV worldwide who still need access to treatment. You can read our press release here.

---

January 31, 2018

Disrupting the U.S. Healthcare System

I continue to be a strong proponent for disrupting and reimagining the U.S. healthcare system, and I believe employers will play a crucial role. In this recent media interview, I share some of my ideas.

---

January 23, 2018

Experiencing Davos for the First Time

Anticipation, expectation and excitement all ran high as I began my journey through Davos today to participate in the World Economic Forum. I am humbled by my surroundings – both the snow-capped mountains as well as the thousands of people participating in the forum. Read more

---

January 9, 2018

Great Day at a Great Conference

Excited to be here at J.P. Morgan’s Healthcare Conference. Mylan is off to a great start to 2018, and I look forward to continuing the important discussion about healthcare and challenging the status quo. I started early this morning with a media interview with Fox Business’s Maria Bartiromo. Read more

---

December 18, 2017

Almost Heaven. West Virginia.

The world is a very big place, but no matter how far away I travel, West Virginia holds a special place in my heart. It’s where I was born and raised, it’s where Mylan was founded nearly 57 years ago and it’s where I began my career with the company. Read more

---

December 17, 2017

Our Hearts Are Still and Always With Those in Puerto Rico

Happy 30th anniversary, Mylan Puerto Rico!

You are part of Puerto Rico’s proud tradition of pharmaceutical manufacturing, and your quality products help deliver better health in the U.S. and Canada – and as far away as Japan. The extra care and attention required to make the important products you do – for conditions such as cancer, autoimmune disorders and diabetes – calls for an exceptional team. I have no doubt that the many patients who use your products deeply appreciate your commitment to excellence. Read more

---

December 5, 2017

States Can and Should Disrupt Healthcare 

Democratic governors gathered this week in New Orleans, where I was invited to participate in a panel discussion regarding the U.S. healthcare system and its future.

I took the opportunity to share some remarkable statistics about the generic pharmaceuticals industry and Mylan’s role within it. For example, did you know that generics now fill 90% of all prescriptions dispensed in the nation but account for only 27% of drug-spending costs? That means brands fill the remaining 10% of all prescriptions yet make up 73% of drug spending. Read more

---

December 1, 2017

Mylan’s Commitment to Expand Access to Cancer Treatments Reaches New Milestone

Mylan is celebrating an important victory today on behalf of patients in the U.S. who have HER2-positive breast cancer or metastatic stomach cancer.

The Food and Drug Administration just approved Ogivri™, the first biosimilar in the U.S. to Herceptin® (trastuzumab), a biologic drug that’s part of a new generation of targeted therapies which have radically changed the way cancer is treated. Mylan co-developed Ogivri with Biocon. The approval is significant because of the tremendous value biosimilars offer. Read More

---

December 1, 2017

World AIDS Day

Today is World AIDS Day, and on this occasion, we mourn the millions of lives lost to the disease already, support and encourage those living with it, and renew our commitment to defeating the virus once and for all. Read More

---

October 24, 2017

What a Difference a Decade Makes

Ten years ago this month, Mylan completed its acquisition of Merck KGaA’s generics business. Through this watershed event we essentially transformed ourselves overnight into one of the world’s leading specialty and generic pharmaceuticals companies.

Mylan already was an American success story, having helped establish generic drugs by the end of the 20th century as the backbone of the U.S. healthcare system. But the industry was changing. Our customers were consolidating, lower-cost imported drugs were flooding into the country and brand pharma companies had become far more aggressive in their attempts to impede competition. Read More

---

September 25, 2017

Equality for all

Over the weekend, the film “Battle of the Sexes” premiered – it chronicles the 1973 tennis match between Billie Jean King and Bobby Riggs, which remains the most watched televised sports event of all time. I was fortunate to get a sneak peek of the movie, thanks to an invitation from my friend Billie Jean King, at its Los Angeles premier. The film reminded me of how far we’ve come as a society in terms of how we value the contributions and capabilities of both men and women. It also reminded me of how far we’ve yet to go and that men and women are still fighting globally for equal access to opportunity. Read More

---

September 5, 2017

Better Health for a Better West Virginia

Last week, I was honored to speak at the West Virginia Chamber’s annual business summit in White Sulphur Springs, W.Va. It’s always great to come home, and I am proud to call West Virginia my home as well as Mylan’s birthplace. As you know, White Sulphur Springs is where Mylan was founded more than 55 years ago by two army buddies who had a vision to provide access to medicine to the good people of rural West Virginia. Today, Mylan is still doing the same thing -- just now on a global scale. Read More

---

August 25, 2017

Parking lot picnics: a great way to bring people together

Sometimes the simplest ways to build friendships and celebrate community are the best ones. This week, I was honored to join Mylan employees in Pittsburgh for a picnic in our office parking lot. We recognized colleagues who achieved milestone anniversaries in 2017, including our President Rajiv Malik who has played an invaluable leadership role with Mylan for 10 years. Read More

---

August 7, 2017

Sharing Mylan’s Impact on U.S. Healthcare at the 2017 DGA Policy Conference

I appreciated the opportunity to attend the Democratic Governors Association 2017 Summer Policy Conference in Aspen over the weekend, where I shared Mylan’s great story with governors, their staff and fellow attendees. I emphasized the scale of our impact on U.S. healthcare – over the past decade Mylan has contributed to more than $180 billion in healthcare savings as a leading manufacturer of generic pharmaceuticals.  Read More

---

June 12, 2017

Generics and Biosimilars Drive Access and Savings for the U.S. Healthcare System

The Association for Accessible Medicines today released their 2017 Generic Drug Access & Savings in the U.S. report. I am always keen to read these findings, because it reinforces how Mylan along with our generics industry peers are part of the solution to address the critical economic burden faced by the U.S. healthcare system.

In the last decade, generic drugs have saved the U.S. healthcare system $1.67 trillion, generating $253 billion in savings in 2016 alone. Nearly 3.9 billion of the total 4.4 billion prescriptions dispensed in the U.S. are for generics. That’s equivalent to generics accounting for almost 90% of prescriptions, but only 26% of the cost. Read More

---

May 30, 2017

Sustaining a Culture that Delivers Better Health for a Better World

I’m truly humbled and honored that tomorrow evening I’ll be receiving Hugh O’Brian Youth’s (HOBY) Albert Schweitzer Leadership Award. HOBY gives this award to individuals who, “through their leadership, have made significant contributions to the education and motivation of youth.”

For those who may not be familiar with HOBY, it was created by actor and humanitarian Hugh O’Brian to help cultivate tomorrow’s leaders by inspiring a global community of youth and volunteers to a life dedicated to leadership, service and innovation. In creating the organization, O’Brian was acting on Dr. Schweitzer’s belief that the most important thing in education is to teach young people to think for themselves – a life lesson that was instilled in me at a very young age. Read More

---

May 16, 2017

Honoring National Women’s Health Week

Sunday marked the beginning of National Women’s Health Week, an annual observance led by the U.S. Department of Health and Human Services (HHS) Office on Women's Health. HHS’s message of empowering women to make their health a priority is a powerful one, and one that we take seriously at Mylan.

What’s remarkable is that the public dialogue around women’s health has only just begun. We know, unfortunately, that women are at a higher risk of facing a range of potential health concerns. Not only that, but certain diseases also can manifest themselves very differently in men than women. It wasn’t until the past couple of decades that there was an acknowledgement by regulatory bodies, government agencies and the scientific community that women were not adequately enrolled in clinical trials. We are now scratching the surface on how the biological differences between men and women can have a meaningful impact on how diseases affect the two sexes. Read More

---

February 15, 2017

A New Look for an Industry That's Always Been About Access

I had the pleasure of attending the Generic Pharmaceutical Association’s annual meeting this week. It’s an important meeting for our industry to rally behind and align on how we can continue to play a meaningful role in expanding access to high quality medicines for patients.

Having just finished a one-year term as chair of the association, this year’s event was particularly meaningful as GPhA launched its new brand – the Association for Accessible Medicines -- to better reflect what our industry means to America's healthcare system.  Read More